GeneTex to introduce new EasyBlot reagent

NewsGuard 100/100 Score

GeneTex, a leading manufacturer of high-quality antibodies, is pleased to announce that they will be launching EasyBlot, a new secondary antibody reagent that eliminates the interference that has long plagued immunoprecipitation (IP) experiments when the IP and western blot primary antibodies are from the same host. IP is a technique that involves the precipitation of a protein antigen out of a solution (e.g., a cellular lysate) through the use of an antibody that specifically binds that protein. This technique can be used to isolate and concentrate a particular protein, as well as any additional proteins to which the antigen binds (i.e., co-immunoprecipitation (co-IP)). However, the heavy and light chains of the denatured IgG used for the IP often mask the signal of the protein of interest on the subsequent western blot.

GeneTex's new EasyBlot reagent is an HRP-conjugated secondary antibody that specifically reacts with the native, non-reduced primary antibody used for the western blot while largely ignoring the reduced, denatured antibody chains of the IP antibody. Using EasyBlot as a second step reagent dramatically decreases the interference caused by the heavy (~50 kDa) and light (~25 kDa) chains of the IgG used for IP, thereby efficiently eliminating any masking of your target signal. This reagent can be utilized in IPs and co-IPs using Protein A-, Protein G-, or agarose-conjugated antibodies.

"We are very excited to offer this product to our customers." says Dr. Chun-Chiang Wen , Product Quality Manager at GeneTex, Inc. "GeneTex's EasyBlot reagent has been thoroughly optimized to ensure that there will be no interference from the heavy and light chains in IP experiments."

GeneTex offers EasyBlot reagents that detect primary antibodies from rabbit, mouse, rat, goat and sheep hosts.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Research unveils bispecific antibodies for B-cell lymphoma treatment